Scott L. Burrows

CIK: 0001853327

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)28 (70.0%)

Position reduction

Option Exercises (M)10 (25.0%)

Derivative conversions

Awards (A)2 (5.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SYRE

Spyre Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (40 total)

SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
1.5K shares at avg. $90.27$135K
SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
2.1K shares at avg. $91.92$193K
SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
229 shares at avg. $93.57$21K
SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
3.1K shares at avg. $92.95$285K
SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Exercise(M)
Direct
7.5K shares at avg. $14.50$109K
SYRE
Spyre Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
600 shares at avg. $89.07$53K
SYRE
Spyre Therapeutics, Inc.
Sep 30, 2026
Sale(S)
Direct
17.5K shares at avg. $89.89$1.6M
SYRE
Spyre Therapeutics, Inc.
Sep 30, 2026
Exercise(M)
Direct
17.5K shares at avg. $14.50$254K
SYRE
Spyre Therapeutics, Inc.
Sep 2, 2026
Sale(S)
Direct
18.2K shares at avg. $89.35$1.6M
SYRE
Spyre Therapeutics, Inc.
Sep 1, 2026
Exercise(M)
Direct
7.5K shares at avg. $14.50$109K
SYRE
Spyre Therapeutics, Inc.
Sep 1, 2026
Sale(S)
Direct
4.4K shares at avg. $87.11$382K
SYRE
Spyre Therapeutics, Inc.
Sep 1, 2026
Sale(S)
Direct
2K shares at avg. $88.03$177K
SYRE
Spyre Therapeutics, Inc.
Sep 1, 2026
Sale(S)
Direct
200 shares at avg. $89.04$18K
SYRE
Spyre Therapeutics, Inc.
Sep 1, 2026
Sale(S)
Direct
900 shares at avg. $86.25$78K
SYRE
Spyre Therapeutics, Inc.
Aug 3, 2026
Sale(S)
Direct
2.3K shares at avg. $96.30$221K
SYRE
Spyre Therapeutics, Inc.
Aug 3, 2026
Sale(S)
Direct
5.1K shares at avg. $95.21$486K
SYRE
Spyre Therapeutics, Inc.
Aug 3, 2026
Exercise(M)
Direct
7.5K shares at avg. $14.50$109K
SYRE
Spyre Therapeutics, Inc.
Aug 3, 2026
Sale(S)
Direct
100 shares at avg. $97.10$10K
SYRE
Spyre Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
5.8K shares at avg. $87.55$506K
SYRE
Spyre Therapeutics, Inc.
Jul 1, 2026
Exercise(M)
Direct
7.5K shares at avg. $14.50$109K
SYRE
Spyre Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
1.7K shares at avg. $88.37$152K
SYRE
Spyre Therapeutics, Inc.
Jun 25, 2026
Exercise(M)
Direct
15K shares at avg. $14.50$218K
SYRE
Spyre Therapeutics, Inc.
Jun 25, 2026
Sale(S)
Direct
5K shares at avg. $87.12$436K
SYRE
Spyre Therapeutics, Inc.
Jun 25, 2026
Sale(S)
Direct
10K shares at avg. $87.14$871K
SYRE
Spyre Therapeutics, Inc.
Jun 1, 2026
Exercise(M)
Direct
7.5K shares at avg. $14.50$109K

		Type	Shares	Price		Ownership
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	1,500	$90.27	$135,405	Direct
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	2,100	$91.92	$193,032	Direct
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	229	$93.57	$21,428	Direct
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	3,071	$92.95	$285,449	Direct
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Exercise(M)	7,500	$14.50	$108,750	Direct
Oct 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	600	$89.07	$53,442	Direct
Sep 30, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	17,500	$89.89	$1,573,075	Direct
Sep 30, 2026	SYRE Spyre Therapeutics, Inc.	Exercise(M)	17,500	$14.50	$253,750	Direct
Sep 2, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	18,232	$89.35	$1,629,029	Direct
Sep 1, 2026	SYRE Spyre Therapeutics, Inc.	Exercise(M)	7,500	$14.50	$108,750	Direct
Sep 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	4,384	$87.11	$381,890	Direct
Sep 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	2,016	$88.03	$177,468	Direct
Sep 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	200	$89.04	$17,808	Direct
Sep 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	900	$86.25	$77,625	Direct
Aug 3, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	2,300	$96.30	$221,490	Direct
Aug 3, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	5,100	$95.21	$485,571	Direct
Aug 3, 2026	SYRE Spyre Therapeutics, Inc.	Exercise(M)	7,500	$14.50	$108,750	Direct
Aug 3, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	100	$97.10	$9,710	Direct
Jul 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	5,775	$87.55	$505,601	Direct
Jul 1, 2026	SYRE Spyre Therapeutics, Inc.	Exercise(M)	7,500	$14.50	$108,750	Direct
Jul 1, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	1,725	$88.37	$152,438	Direct
Jun 25, 2026	SYRE Spyre Therapeutics, Inc.	Exercise(M)	15,000	$14.50	$217,500	Direct
Jun 25, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	5,000	$87.12	$435,600	Direct
Jun 25, 2026	SYRE Spyre Therapeutics, Inc.	Sale(S)	10,000	$87.14	$871,400	Direct
Jun 1, 2026	SYRE Spyre Therapeutics, Inc.	Exercise(M)	7,500	$14.50	$108,750	Direct

1-25 of 40 transactions

About Burrows Scott L

Burrows Scott L (SEC CIK 0001853327) files insider reports with the SEC as Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE).

Signal8 holds 13 ownership filings by Burrows Scott L, all Form 4s, filed between Sep 5, 2024 and Oct 2, 2026. Those filings report 40 transactions, from Sep 3, 2024 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Burrows Scott L's filings is in WALTHAM, MA.

Recent filings by Burrows Scott L

Oct 1, 2026: Open-market sales of SYRE shares (4 lines, Form 4, code S).
Oct 1, 2026: Option exercise of SYRE shares (Form 4, code M).
Oct 1, 2026: Open-market sale of SYRE shares (Form 4, code S).
Sep 30, 2026: Open-market sale of SYRE shares (Form 4, code S).
Sep 30, 2026: Option exercise of SYRE shares (Form 4, code M).

Other insiders filing for Spyre Therapeutics, Inc. (SYRE)

King-Jones Heidy
Turtle Cameron, Chief Executive Officer
Albers Jeffrey W., Director
Sloan Sheldon, Chief Medical Officer
Fairmount Funds Management LLC, Director
HENDERSON MICHAEL THOMAS, Director

How to read Form 4 transaction codes